Acute leukemias and complicated lymphomas: pearls to optimize management when patients stay local

2.

Cronin

KA

,

Scott

S

,

Firth

AU

, et al.

Annual report to the nation on the status of cancer, part 1: national cancer statistics

.

Cancer

.

202

;

128(24)

:

4251

-

4284

.

doi:10.1002/cncr.34479

.

3.

Nauffal

M

,

Werner

L

,

Ni

J

,

Stone

RM

,

DeAngelo

DJ

,

McDonnell

AM

.

Rate of differentiation syndrome in patients based on timing of initial all-trans retinoic acid administration

.

Leuk Res Rep

.

2019

;

12

:

100189

.

doi:10.1016/j.lrr.2019.100189

.

4.

Abaza

Y

,

Kantarjian

H

,

Garcia-Manero

G

, et al.

Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab

.

Blood

.

2017

;

129

(

10

):

1275

-

1283

.

doi:10.1182/blood-2016-09-736686

.

5.

Iland

HJ

,

Collins

M

,

Bradstock

K

, et al;

Australasian Leukaemia and Lymphoma Group

.

Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial

.

Lancet Haematol

.

2015

;

2

(

9

):

e357

-

e366

.

doi:10.1016/S2352-3026(15)00115-5

.

6.

Lancet

JE

,

Moseley

AB

,

Coutre

SE

, et al.

A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)

.

Blood Adv

.

2020

;

4

(

8

):

1683

-

1689

.

doi:10.1182/bloodadvances.2019001278

.

7.

Wang

H-Y

,

Gong

S

,

Li

G-H

, et al.

An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial)

.

Blood Cancer J

.

2022

;

12

(

11

):

158

.

doi:10.1038/s41408-022-00753-y

.

8.

Halpern

AB

,

Walter

RB

.

Practice patterns and outcomes for adults with acute myeloid leukemia receiving care in community vs academic settings

.

Hematology Am Soc Hematol Educ Program

.

2020

;

2020

(

1

):

129

-

134

.

doi:10.1182/hematology.2020000097

.

9.

Osman

AEG

,

Anderson

J

,

Churpek

JE

, et al.

Treatment of acute promyelocytic leukemia in adults

.

J Oncol Pract

.

2018

;

14

(

11

):

649

-

657

.

doi:10.1200/JOP.18.00328

.

10.

Lo-Coco

F

,

Avvisati

G

,

Vignetti

M

, et al;

Gruppo Italiano Malattie Ematologiche dell'Adulto; German-Austrian Acute Myeloid Leukemia Study Group

;

Study Alliance Leukemia

.

Retinoic acid and arsenic trioxide for acute promyelocytic leukemia

.

N Engl J Med

.

2013

;

369

(

2

):

111

-

121

.

doi:10.1056/NEJMoa1300874

.

11.

Burnett

AK

,

Russell

NH

,

Hills

RK

, et al;

UK National Cancer Research Institute Acute Myeloid Leukaemia Working Group

.

Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial

.

Lancet Oncol

.

2015

;

16

(

13

):

1295

-

1305

.

doi:10.1016/s1470-2045(15)00193-x

.

12.

Ravandi

F

,

Estey

E

,

Jones

D

, et al.

Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin

.

J Clin Oncol

.

2009

;

27

(

4

):

504

-

510

.

doi:10.1200/JCO.2008.18.6130

.

13.

Dunleavy

K

,

Fanale

MA

,

Abramson

JS

, et al.

Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study

.

Lancet Haematol

.

2018

;

5

(

12

):

e609

-

e617

.

doi:10.1016/s2352-3026(18)30177-7

.

14.

Bartlett

N

,

Wyndham

W

,

Jung

SH

, et al.

Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial alliance/CALGB 50303

.

J Clin Oncol

.

2019

;

37

:(

21

):

1790

-

1799

.

doi:10.1200/JCO.18.01994

.

15.

Tilly

H

,

Morschhauser

F

,

Sehn

LH

, et al.

Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma

.

N Engl J Med

.

2022

;

386

(

4

):

351

-

363

.

doi:10.1056/NEJMoa2115304

.

16.

Frontzek

F

,

Karsten

I

,

Schmitz

N

,

Lenz

G

.

Current options and future perspectives in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma

.

Ther Adv Hematol

.

2022

;

13

:

20406207221103321

.

doi:10.1177/20406207221103321

.

17.

Neelapu

SS

,

Locke

FL

,

Bartlett

NL

, et al.

Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma

.

N Engl J Med

.

2017

;

377

(

26

):

2531

-

2544

.

doi:10.1056/NEJMoa1707447

.

18.

Schuster

SJ

,

Bishop

MR

,

Tam

CS

, et al;

JULIET Investigators

.

Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma

.

N Engl J Med

.

2019

;

380

(

1

):

45

-

56

.

doi:10.1056/NEJMoa1804980

.

19.

Locke

FL

,

Ghobadi

A

,

Jacobson

CA

, et al.

Long-term safety and activity of axicabtageneciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial

.

Lancet Oncol

.

2019

;

20

(

1

):

31

-

42

.

doi:10.1016/S1470-2045(18)30864-7

.

20.

Makita

S

,

Yoshimura

K

,

Tobinai

K

.

Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma

.

Cancer Sci

.

2017

;

108

(

6

):

1109

-

1118

.

doi:10.1111/cas.13239

.

21.

Bishop

MR

,

Dickinson

M

,

Purtill

D

, et al.

Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma

.

N Engl J Med

.

2022

;

386

(

7

):

629

-

639

.

doi:10.1056/NEJMoa2116596

.

22.

Westin

JR

,

Oluwole

O

,

Kersten

MJ

, et al.

Survival with axicabtagene ciloleucel in large B-cell lymphoma

.

N Engl J Med

.

2023

;

389

:

148

-

157

.

doi:10.1056/NEJMoa2301665

.

23.

Sehgal

A

,

Hoda

D

,

Riedell

PA

, et al.

Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study

.

Lancet Oncol

.

2022

;

23

(

8

):

1066

-

1077

.

doi:10.1016/S1470-2045(22)00339-4

.

24.

Bachy

E

,

Le Gouill

S

,

Di Blasi

R

, et al.

A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma

.

Nat Med

.

2022

;

28

(

10

):

2145

-

2154

.

doi:10.1038/s41591-022-01969-y

.

25.

Sawalha

Y

.

Relapsed/refractory diffuse large B-cell lymphoma: a look at the approved and emerging therapies

.

J Pers Med

.

2021

;

11

(

12

):

1345

.

doi:10.3390/jpm11121345

.

26.

Falchi

L

,

Vardhana

S

,

Salles

GA

.

Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities

.

Blood

.

2023

;

141

(

5

):

467

-

480

.

doi:10.1182/blood.2021011994

.

27.

Dickinson

MJ

,

Carlo-Stella

C

,

Morschhauser

F

, et al.

Glofitamab for relapsed or refractory diffuse large B-cell lymphoma

.

N Engl J Med

.

2022

;

387

(

24

):

2220

-

2231

.

doi:10.1056/NEJMoa2206913

.

28.

Czuczman

MS

,

Goy

A

,

Lamonica

D

,

Graf

DA

,

Munteanu

MC

,

van der Jagt

RH

.

Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings

.

Ann Hematol

.

2015

;

94

(

12

):

2025

-

2032

.

doi:10.1007/s00277-015-2478-9

.

29.

Wang

ML

,

Rule

S

,

Martin

P

, et al.

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

.

N Engl J Med

.

2013

;

369

(

6

):

507

-

516

.

doi:10.1056/NEJMoa1306220

.

30.

Wang

M

,

Rule

S

,

Zinzani

PL

, et al.

Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial

.

Lancet

.

2018

;

391

(

10121

):

659

-

667

.

doi:10.1016/s0140-6736(17)33108-2

.

31.

Song

Y

,

Zhou

K

,

Zou

D

, et al.

Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study

.

Blood

.

2022

;

139

(

21

):

3148

-

3158

.

doi:10.1182/blood.2021014162

.

32.

Wang

Y

,

Jain

P

,

Locke

FL

, et al.

Brexucabtagene Autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US lymphoma CAR T consortium

.

J Clin Oncol

.

2023

;

41

(

14

):

2594

-

2606

.

doi:10.1200/jco.22.01797

.

33.

Buckley

SA

,

Jimenez-Sahagun

D

,

Othus

M

,

Walter

RB

,

Lee

SJ

.

Quality of life from the perspective of the patient with acute myeloid leukemia: determinants of QOL in patients with AML

.

Cancer

.

2018

;

124

(

1

):

145

-

152

.

doi:10.13039/100000002

.

34.

Davidoff

AJ

,

Long

JB

,

Neparidze

N

, et al.

Oncologist sub-specialization, care setting, and multiple myeloma treatment and outcomes

.

Blood

.

2020

;

136

(

suppl 1

):

2

-

3

.

doi:10.1182/blood-2020-140728

.

35.

Unger

JM

,

Hershman

DL

,

Till

C

, et al. “

When offered to participate”: a systematic review and meta-analysis of patient agreement to participate in cancer clinical trials

.

J Natl Cancer Inst

.

2021

;

113

(

3

):

244

-

257

.

doi:10.1093/jnci/djaa155

.

36.

Gordan

L

,

Blazer

M

,

Saundankar

V

,

Kazzaz

D

,

Weidner

S

,

Eaddy

M

.

Cost differences associated with oncology care delivered in a community setting versus a hospital setting: a matched-claims analysis of patients with breast, colorectal, and lung cancers

.

J Oncol Pract

.

2018

;

14

(

12

):

e729

-

e738

.

doi:10.1200/jop.17.00040

.

37.

Jillella

AP

,

Arellano

ML

,

Gaddh

M

, et al.

Comanagement strategy between academic institutions and community practices to reduce induction mortality in acute promyelocytic leukemia

.

JCO Oncol Pract

.

2021

;

17

(

4

):

e497

-

e505

.

doi:10.1200/op.20.00395

.